{'fraction_non_alphanumeric': 0.01685891748003549, 'fraction_numerical': 0.01064773735581189, 'mean_word_length': 4.872395833333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Sleeping sickness: one hundred years of control strategy evolution].

Sleeping sickness has been known since the fifteenth century but the real progress in the knowledge of the disease occurred in the nineteenth century with the development of microscopy. From 1841 to 1901 the parasites and their vectors have been identified, the symptomatology and the epidemiology have been described. However, due to absence of any effective cure, the campaign against the disease was still based on the isolation of the patients and the transfer of exposed populations. The discovery of atoxyl in 1905 provided doctors with their first therapeutic weapon and, in 1910, the first action of vector control was undertaken with success in the Island of Principe. Between the two world conflicts, Jamot published the rules to fight against major outbreaks. Their application in Oubangui-Chari, in Cameroon and in French Occidental Africa brought tremendous results and signed the triumph of the mobile unit concept. Success which will not be denied until the sixties when the disease was believed to be eradicated. From the sixties to the nineties, the concept of the integration of prevention and care added to the exclusion of any vertical system will result in a progressive reniewed outbreak of the sleeping sickness in the known foci. As a paradox, it is a time rich in discovery as regards diagnosis, treatment and entomology. In 1994, the World Health Organisation got concerned with the situation of the disease in Central Africa where the outbreak of the disease reinforced. A second paradox appeared; it is the next to total disinterest from the politics and fund raisers which will save the disease. Today, sleeping sickness is the typical example of the orphan disease, a show case brandished by all the good souls. In 2001, an agreement between the WHO and the pharmaceutical industry brings back the financial funds required to fight the disease. Basically, it is a matter of resuming the action by using what is still existing and by creating new strategies considering the extreme lack of human and logistical resources. The objective is to eradicate the sleeping sickness as a public health problem. The challenge is huge, but is on the way to success.